Omeros Corporation (OMER) Fair Value 2026

OMER · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

3.8 /10

32 fundamental signals · 1 models active

Value Trap Risk

WARN (49/100)

Quick Summary — As of 2026-08-28, Omeros Corporation (OMER) trades at $18.61. QOC: 3.8/10. Value Trap Risk: 49/100 (WARN). 1/13 models active.

Key Facts

Ticker
OMER
Price
$18.61
Quality Score
3.8/10
Value Trap Risk
49/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Value Trap score of 49 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give OMER?

1 Intrinsic Value Models vs. Current Price ($18.61)

Core Models (Unlocked)
Model Fair Value Upside
Relative · Medium Conviction
 $6.10 -67.2%

All Models Active

All 1 models are displayed above.

What Is Omeros Corporation (OMER) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Omeros Corporation's intrinsic value is estimated at $6.10, suggesting the stock is overvalued at its current price of $18.61. With 1 out of 1 models flagging downside (-67.2% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About OMER?

1 of 13 models are currently active for OMER. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does OMER Rank in Biotechnology?

Among 625 Biotechnology stocks, OMER ranks #553 by Quality of Company score. CirclFi's QOC score of 3.8/10 evaluates 32 fundamental signals. A score of 3.8 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a life sciences company, Omeros Corporation operates in a sector where cash runway (months) is a critical driver of valuation. Investors evaluating OMER should weigh these sector-specific dynamics alongside our model-derived fair values.

Is OMER a Value Trap?

CirclFi's Value Trap algorithm assigns OMER a score of 49/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Omeros Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Omeros Corporation's fundamental quality profile registers 3.8/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every OMER valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across OMER's 1 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Omeros Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ESLAEstrella Immunopharma, Inc.QOC 3.8VORVor Biopharma Inc.QOC 3.8ACUTAccuStem Sciences, Inc.QOC 3.8TVGNTevogen Bio Holdings Inc.QOC 3.8BCLIBrainstorm Cell Therapeutics Inc.QOC 3.8OCEAOcean Biomedical, Inc.QOC 3.8ZVRAZevra Therapeutics, Inc.QOC 6.5PULMPulmatrix, Inc.QOC 5.4MISTMilestone Pharmaceuticals Inc.QOC 4.7EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: ESLA · VOR · ACUT · TVGN · BCLI · OCEA · ZVRA · PULM · MIST · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to OMER?

7 companies across all industries closest to OMER’s Quality of Company score of 3.8/10.

CSHRCoinShares PLCQOC 3.8ALMRAlamar Biosciences, Inc.QOC 3.8BASABasanite, Inc.QOC 3.8EXYNExyn Technologies, Inc.QOC 3.8RNGCRanger Gold Corp.QOC 3.8QCLSQ/C Technologies, Inc.QOC 3.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CSHR · ALMR · BASA · EXYN · RNGC · QCLS · NVDA

Where Does OMER Sit in CirclFi's Biotechnology Rankings?

OMER is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Omeros Corporation’s Valuation?

What is Omeros Corporation's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Omeros Corporation (OMER). The Quality of Company score is 3.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is OMER overvalued or undervalued right now?

At $18.61, 0 of 1 active models suggest OMER may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Omeros Corporation's business model in Biotechnology.

What does a Quality of Company score of 3.8 mean for OMER?

Omeros Corporation's QOC of 3.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on OMER?

CirclFi analyzes OMER with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is OMER a value trap in 2026?

Omeros Corporation's Value Trap score is 49/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Omeros Corporation (OMER) a Quality of Company score of 3.8/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/OMER/ · Methodology
Primary sources for this OMER valuation
  • Financial statements: Omeros Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0001285819) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for OMER as of ; valuations recomputed .